Newron Pharmaceuticals Spa Stock Revenue
| NWRN Stock | CHF 7.20 0.08 1.10% |
Newron Pharmaceuticals SpA fundamentals help investors to digest information that contributes to Newron Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Newron Stock. The fundamental analysis module provides a way to measure Newron Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Newron Pharmaceuticals stock.
Newron |
Newron Pharmaceuticals SpA Company Revenue Analysis
Newron Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Newron Pharmaceuticals Revenue | 5.76 M |
Most of Newron Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Newron Pharmaceuticals SpA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Newron Pharmaceuticals SpA reported 5.76 M of revenue. This is 99.92% lower than that of the Healthcare sector and 99.22% lower than that of the Biotechnology industry. The revenue for all Switzerland stocks is 99.94% higher than that of the company.
Newron Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Newron Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Newron Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Newron Pharmaceuticals by comparing valuation metrics of similar companies.Newron Pharmaceuticals is currently under evaluation in revenue category among its peers.
Newron Fundamentals
| Return On Equity | -8.4 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (2.44) % | |||
| Operating Margin | (1.84) % | |||
| Current Valuation | 32.84 M | |||
| Shares Outstanding | 17.85 M | |||
| Shares Owned By Insiders | 4.96 % | |||
| Shares Owned By Institutions | 7.28 % | |||
| Price To Earning | (11.88) X | |||
| Price To Book | 7.98 X | |||
| Price To Sales | 3.95 X | |||
| Revenue | 5.76 M | |||
| Gross Profit | 5.76 M | |||
| EBITDA | (11.76 M) | |||
| Net Income | (14.9 M) | |||
| Cash And Equivalents | 58.99 M | |||
| Cash Per Share | 3.31 X | |||
| Total Debt | 42.93 M | |||
| Debt To Equity | 0.70 % | |||
| Current Ratio | 13.90 X | |||
| Book Value Per Share | (0.29) X | |||
| Cash Flow From Operations | (11.45 M) | |||
| Earnings Per Share | (0.85) X | |||
| Target Price | 4.35 | |||
| Number Of Employees | 25 | |||
| Beta | 1.11 | |||
| Market Capitalization | 81.91 M | |||
| Total Asset | 50.49 M | |||
| Z Score | 0.6 | |||
| Net Asset | 50.49 M |
About Newron Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Newron Pharmaceuticals SpA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Newron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Newron Pharmaceuticals SpA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Newron Stock Analysis
When running Newron Pharmaceuticals' price analysis, check to measure Newron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Newron Pharmaceuticals is operating at the current time. Most of Newron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Newron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Newron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Newron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.